The underlying fundamentals of Tysabri business appear to be strong, appear to be broad and consistent. And in some ways the underlying fundamentals of the business are running slightly ahead of the current revenue, given some of the challenges in both FX and certain areas of our rest of world/European business.

My third area of commentary, before I turn it to Nigel, is just a broad restatement of parts of our strategy. As we have done and continue to do and will continue to do, we remain resolutely focused on improving all fundamentals of our business. That includes, from a financial point of view, utilization of our balance sheet to strengthen our capital structure; working closely with Biogen on the positioning of Tysabri in its current business and exploring prudently future businesses around Tysabri; being innovative in our science area and taking a disciplined approach to different targets which may, over time, lead to clinical assets which ultimately can lead to patient and commercial assets. So our strategy remains consistent. Our focus remains the same. As we have done consistently over the last number of years, we continue to focus on providing shareholders with a value proposition that allows for upside at risk dynamics which continue to decrease as the business moves forward.

Read the rest of this transcript for free on

If you liked this article you might like

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'

Despite Shkreli Drama, Retrophin Looks Interesting Now

Celtic Tiger Tries to Roar Again

Cramer's 6 Stocks in 60 Seconds: PRGO CREE HOG GME ORCL MHK (Update 1)